| Literature DB >> 35013530 |
Jing Wang1, Shao-Yan Xi2, Qi Zhao3, Yun-Fei Xia4, Qun-Ying Yang5, Hai-Ping Cai5, Fang Wang6, Yi-Ying Zhao5, Huan-Jing Hu3, Zhi-Hui Yu5, Fu-Rong Chen5, Peng-Fei Xu5, Ri-Zhen Xu5, Jian Wang5, Ji Zhang5, Chao Ke5, Xiang-Heng Zhang5, Fu-Hua Lin5, Cheng-Cheng Guo5, Yan-Chun Lv7, Cong Li5,8, Hai-Tao Xie8, Qian Cui9, Hong-Mei Wu9, Yan-Hui Liu9, Zhi Li9, Hong-Kai Su5, Jing Zeng2, Fu Han8, Zhao-Jie Li10, Ke Sai11, Zhong-Ping Chen12.
Abstract
Although there have been recent advances in the molecular pathology of ependymomas, little is known about the underlying molecular evolution during its development. Here, we assessed the clinical, pathological and molecular evolutionary process of ependymoma recurrence in a 9-year-old patient who had seven recurrences of supratentorial ependymoma and died from intracranial multiregional recurrences at the age of 19 years old. Whole-genome sequencing (WGS) of 7 tumor samples (1 primary and 6 subsequent recurrent tumors) was performed to elucidate the mutation landscape and identify potential driver mutations for tumor evolution. The genetic profiles of the seven tumor specimens showed significant heterogeneity and suggested a highly branched evolutionary pattern. The mutational signatures and chromothripsis changed with treatments. Strikingly, adhesion G protein-coupled receptor L3 (ADGRL3, also known as Latrophilins 3, LPNH3) was found to be consistently mutated during the entire disease process. However, Sanger sequencing of other 78 ependymoma patients who underwent surgery at our institution showed no genetic alteration of ADGRL3, as found in the present case. The mRNA levels of ADGRL3 were significantly lower in ependymomas (n = 36), as compared with normal brain tissue (n = 3). Grade III ependymomas had the lowest ADGRL3 expression. Moreover, ependymomas with lower mRNA level of ADGRL3 had shorter overall survival. Our findings, therefore, demonstrate a rare evolutionary process of ependymoma involving ADGRL3.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35013530 DOI: 10.1038/s41374-021-00721-3
Source DB: PubMed Journal: Lab Invest ISSN: 0023-6837 Impact factor: 5.502